Clexio Biosciences Ltd.
🇮🇱Israel
- Country
- 🇮🇱Israel
- Ownership
- Private
- Established
- 2018-03-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.clexio.com
Clinical Trials
3
Active:1
Completed:2
Trial Phases
1 Phases
Phase 2:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 2
3 (100.0%)A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder
Phase 2
Active, not recruiting
- Conditions
- Adjunctive Treatment of Major Depressive Disorder (MDD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- Clexio Biosciences Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT06340958
- Locations
- 🇺🇸
Clinical Site 139, La Jolla, California, United States
🇺🇸Clinical Site 131, Lafayette, California, United States
🇺🇸Clinical Site 130, Upland, California, United States
A Study of CLE-400 (Topical Gel) for the Treatment of Chronic Pruritus in Adult Subjects with Notalgia Paresthetica
Phase 2
Completed
- Conditions
- Chronic Pruritus in Adult Subjects with Notalgia Paresthetica (NP)
- Interventions
- Drug: Vehicle
- First Posted Date
- 2024-02-16
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Clexio Biosciences Ltd.
- Target Recruit Count
- 59
- Registration Number
- NCT06262607
- Locations
- 🇺🇸
Clinical site 11, Bryant, Arkansas, United States
🇺🇸Clinical Site 21, Fremont, California, United States
🇺🇸Clinical site 01, Coral Gables, Florida, United States
A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study
Phase 2
Completed
- Conditions
- Adjunctive Treatment of Major Depressive Disorder
- Interventions
- Drug: placebo
- First Posted Date
- 2019-09-26
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Clexio Biosciences Ltd.
- Target Recruit Count
- 130
- Registration Number
- NCT04103892
- Locations
- 🇺🇸
Clinical Site 126, Bentonville, Arkansas, United States
🇺🇸Clinical Site 120, Little Rock, Arkansas, United States
🇺🇸Clinical Site 129, Little Rock, Arkansas, United States
News
No news found